Triodos Investment Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $40.2M | Sell |
501,858
-3,000
| -0.6% | -$247K | 3.04% | 11 |
|
|
2025
Q4 | $43.5M | Sell |
504,858
-4,000
| -0.8% | -$328K | 3.15% | 9 |
|
|
2025
Q3 | $39.6M | Sell |
508,858
-400
| -0.1% | -$31.3K | 2.86% | 11 |
|
|
2025
Q2 | $39.8M | Buy |
509,258
+1,500
| +0.3% | +$112K | 2.99% | 11 |
|
|
2025
Q1 | $36M | Sell |
507,758
-2,200
| -0.4% | -$157K | 2.96% | 13 |
|
|
2024
Q4 | $37.8M | Buy |
509,958
+700
| +0.1% | +$49K | 3.05% | 13 |
|
|
2024
Q3 | $33.6M | Buy |
509,258
+101,300
| +25% | +$7.36M | 2.65% | 14 |
|
|
2024
Q2 | $37.7M | Hold |
407,958
| – | – | 3.29% | 11 |
|
|
2024
Q1 | $39M | Buy |
407,958
+39,700
| +11% | +$3.33M | 3.53% | 8 |
|
|
2023
Q4 | $28.1M | Sell |
368,258
-6,000
| -2% | -$417K | 2.74% | 16 |
|
|
2023
Q3 | $25.9M | Sell |
374,258
-16,742
| -4% | -$1.35M | 2.75% | 14 |
|
|
2023
Q2 | $36.9M | Sell |
391,000
-2,750
| -0.7% | -$239K | 3.68% | 8 |
|
|
2023
Q1 | $32.6M | Sell |
393,750
-5,000
| -1% | -$393K | 3.66% | 7 |
|
|
2022
Q4 | $29.8M | Sell |
398,750
-61,100
| -13% | -$4.71M | 3.92% | 9 |
|
|
2022
Q3 | $38M | Buy |
459,850
+49,300
| +12% | +$4.74M | 5.43% | 3 |
|
|
2022
Q2 | $39M | Buy |
410,550
+750
| +0.2% | +$77.6K | 5.5% | 2 |
|
|
2022
Q1 | $48.2M | Hold |
409,800
| – | – | 6.16% | 2 |
|
|
2021
Q4 | $53.1M | Buy |
409,800
+13,200
| +3% | +$1.54M | 6.94% | 2 |
|
|
2021
Q3 | $44.9M | Sell |
396,600
-7,000
| -2% | -$799K | 6.03% | 3 |
|
|
2021
Q2 | $41.8M | Buy |
403,600
+1,200
| +0.3% | +$113K | 5.6% | 3 |
|
|
2021
Q1 | $33.7M | Buy |
402,400
+28,000
| +7% | +$2.37M | 5.33% | 4 |
|
|
2020
Q4 | $34.2M | Buy |
374,400
+14,500
| +4% | +$1.2M | 5.64% | 2 |
|
|
2020
Q3 | $28.7M | Buy |
359,900
+77,400
| +27% | +$6.04M | 5.92% | 3 |
|
|
2020
Q2 | $19.5M | Sell |
282,500
-32,800
| -10% | -$2.33M | 4.61% | 7 |
|
|
2020
Q1 | $19.8M | Buy |
315,300
+72,900
| +30% | +$5.26M | 5.58% | 5 |
|
|
2019
Q4 | $18.9M | Sell |
242,400
-1,800
| -0.7% | -$141K | 4.21% | 8 |
|
|
2019
Q3 | $17.9M | Sell |
244,200
-85,800
| -26% | -$6.03M | 4.54% | 7 |
|
|
2019
Q2 | $20.3M | Sell |
330,000
-26,700
| -7% | -$1.61M | 4.69% | 6 |
|
|
2019
Q1 | $22.7M | Sell |
356,700
-33,900
| -9% | -$1.93M | 4.6% | 8 |
|
|
2018
Q4 | $19.9M | Sell |
390,600
-108,900
| -22% | -$5.51M | 4.29% | 7 |
|
|
2018
Q3 | $29M | Sell |
499,500
-25,500
| -5% | -$1.25M | 5.02% | 2 |
|
|
2018
Q2 | $25.5M | Buy |
+525,000
| New | +$24.5M | 4.78% | 2 |
|
Other funds holding EW
VCM
VPM
Triodos Investment Management's EW Position: Q1 2026 in Review
Triodos Investment Management reduced its Edwards Lifesciences (EW) stake by 0.59% in Q1 2026, selling an estimated $247K and leaving 501,858 shares worth $40.2M. The position accounts for 3.04% of the portfolio, ranked #11.
Triodos Investment Management first reported a position in EW in Q2 2018 and has held it in 32 quarters since. The position peaked at $53.1M in Q4 2021. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Triodos Investment Management held 501,858 shares of Edwards Lifesciences worth $40.2M as of Q1 2026.
- Triodos Investment Management sold 3,000 Edwards Lifesciences shares in Q1 2026, an estimated $247K.
- Edwards Lifesciences made up 3.04% of Triodos Investment Management's portfolio in Q1 2026, its #11 holding.
- Triodos Investment Management first reported a position in Edwards Lifesciences in Q2 2018 and has held it in 32 quarters since.
- Triodos Investment Management's Edwards Lifesciences position peaked at $53.1M in Q4 2021.
- 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Triodos Investment Management's 13F filing for Q1 2026, filed 7 May 2026.